BRIEF-Mateon Therapeutics terminates FOCUS study in ovarian cancer
Sept 26 (Reuters) – Mateon Therapeutics Inc:
* Announces termination of focus study in ovarian cancer and restructuring to prioritize OXi4503 for AML
* Company to reduce headcount, concentrate on OXi4503 for Acute Myeloid Leukemia (AML)
* Remaining members of senior management team will take 50% salary reductions, effective immediately
* Implementing various cost reduction measures, which includes decrease in co’s workforce of about 60% since beginning of year Source text for Eikon: Further company coverage:
Source link
#USA #News #USnews #worldnews #headlinenews #Breakingnews #weathernews #UnitedStates news #CanadianNews #weatherforecast top news #stories, #hourlyweather #Reuters
Related News
How Tax Reform Will Impact the Trade Deficit – Markets and Finance
Dec.21 — James Lucier, managing director at Capital Alpha Partners, discusses the impact of tax Read More
Annual New Year’s Day ‘polar bear dip’ cancelled in Toronto
TORONTO – The cold snap gripping much of Canada is even keeping the polar bear Read More